MSB 1.40% $1.09 mesoblast limited

Colitis Indication

  1. 790 Posts.
    lightbulb Created with Sketch. 91

    When you look at the FDA clinical trials site there are still two trials that the site says are still recruiting patients:

    Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Crohn's Colitis (NCT04548583), and Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Ulcerative Colitis (NCT04543994).
    We are supposed to have the final results of these two trials sometime in October 2023. Has anyone have any news about the final results of these trials and why they are still recruiting patients? They have already published the interim results, which was promising.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.09
Change
0.015(1.40%)
Mkt cap ! $1.238B
Open High Low Value Volume
$1.11 $1.12 $1.08 $11.51M 10.52M

Buyers (Bids)

No. Vol. Price($)
2 17804 $1.09
 

Sellers (Offers)

Price($) Vol. No.
$1.09 230637 5
View Market Depth
Last trade - 16.10pm 03/05/2024 (20 minute delay) ?
Last
$1.09
  Change
0.015 ( 1.85 %)
Open High Low Volume
$1.10 $1.12 $1.08 1937390
Last updated 15.59pm 03/05/2024 ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.